South Korea conducive for pharma and biotech companies for its rapidly growing local economy and regulatory environment.
In an event at its new branch office attended by key customers and business associates, Vetter鈥檚 senior management representatives presented the company鈥檚 service portfolio along with its growth strategy for South Korea and the Asia Pacific (APAC) region. In addition, attendees were introduced to Mr. Michael Yi who will manage the office in his role as business development manager for Vetter Pharma International GmbH, South Korea. Mr. Yi, who is based in Songdo, has pharmaceutical experience in responsible business development roles at several companies. He reports to Ms. Chervee Ho in her role as director key account management Asia Pacific.
A rapidly growing local economy, combined with a regulatory environment conducive to the industry is a strong incentive for doing business in the country. And, because the population is aging rapidly with corresponding needs for adequate medication, South Korea demonstrates strong commitment to the pharmaceutical market through investing and supporting campaigns in R&D that contribute to innovative healthcare products. With its branch office, Vetter is well positioned to support its existing South Korean business as well as that of new local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.
Click here for the complete issue.